1-Bromopropane (1-BP); Regulation Under the Toxic Substances Control Act (TSCA)
EPA proposes to regulate 1-bromopropane (1-BP) under TSCA due to unreasonable human health risks. Med-spas using 1-BP in products (e.g., solvents, adhesives) must monitor for final rule and prepare to substitute or implement exposure controls.
Aforeworn detected this change in the Med-Spa & Aesthetics Clinics space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Med-spas and aesthetics clinics using products containing 1-bromopropane (e.g., certain solvents, degreasers, or adhesives). should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comment period ends October 7, 2024. Final rule expected within 1-2 years.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Med-Spa & Aesthetics Clinics continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
EPA proposed to regulate 1-BP under TSCA, which may restrict or ban its use, require workplace protections, or mandate reporting.
Who it affects
Med-spas and aesthetics clinics using products containing 1-bromopropane (e.g., certain solvents, degreasers, or adhesives).
What you must do
Identify any products containing 1-BP in your facility and review the proposed rule to determine if your operations are affected. Prepare to comply with final rule (expected within 1-2 years).
Deadline
Comment period ends October 7, 2024. Final rule expected within 1-2 years.
Never miss a change like this again
Aforeworn watches Med-Spa & Aesthetics Clinics around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Med-Spa & Aesthetics Clinics
- FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
- Accolade Pacemaker Devices by Boston Scientific and Potential Need for Early Device Replacement - FDA Safety Communication
- Heart Pump Correction: Abiomed Issues Correction for Automated Impella Controllers
- Disruptions in Availability of Breast Biopsy Needles - Letter to Health Care Providers
- UPDATE: Hintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure: FDA Safety Communication